All of Crossject's employees work every day as a team to develop innovative life-saving solutions and make them a reality for patients. Our unprecedented approach to the administration of emergency medicines mobilizes not only our teams but also our industrial and financial partners to act on a patient lifesaving mission across the world.
Our needle-free device ZENEO® decisively simplifies the patient-side management of disorders requiring auto-injectables. Our technology is compatible with more than 100 molecules covering a large spectrum of pathologies. It is quite simply a revolution for the administration of numerous treatments.
Our expertise is unmatched worldwide. It gives us a head start but also inspires us to act responsibly for our patients and their family.
Considering the characteristics of our product, its intuitiveness, ease of use and rapid administration, we have decided to prioritize our efforts on emergency treatments.
With our unique know-how, we aim to become a world leader in the self-administration of emergency needle free injectables.
From the solid foundation of its unmatched technology, Crossject aims to become the world's leading pharmaceutical laboratory for emergency needle free auto-injectables.
Today, after 20 years of focused R&D, Crossject offers an incomparable auto-injection device protected by 400 patents until 2036.
To always move forward, Crossject has united a vanguard team of specialists from a range of industries and thus gathered the expertise it needs to empower each step of its evolution.
To save lives simply
The raison d'être of the revolutionary, needle-free auto-injection system ZENEO® is nothing less than to save lives in vital emergencies.